AOP Orphan Pharmaceuticals AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AOP Orphan Pharmaceuticals AG
Strides Pharma’s biosimilar teriparatide version of Forsteo has been granted a positive opinion by the EMA’s CHMP, setting the firm up for a pan-European marketing authorization along with Viatris’ pirfenidone generic rival to Esbriet and AOP Orphan Pharmaceuticals’ sugammadex generic of Bridion.
The European Medicines Agency said it was possible to use immunobridging studies to authorize COVID-19 vaccines now that a number of COVID-19 vaccines authorized in the EU are proven to be safe and effective and can be used as comparators in trials.
Keeping Track: GSK’s Priorix Makes Three Novel US FDA CBER Approvals In 2022; Two CV Drugs Among Recent NDAs
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Roche’s Phase III of tominersen in Huntington's disease has been stopped after an independent interim review, but with no new or emerging safety signals reported, analysts presume efficacy was the problem.
- Generic Drugs
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Rigi Orphan Inc, USA